Tag: Opinion

COPENHAGEN, Denmark, July 22, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...

SANTA BARBARA, Calif., June 29, 2022 /PRNewswire/ -- As we celebrate Pride Month, it's important to reflect on the progress that has been made for the LGBTQIA community. And who ...

-- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORENCE, Italy, May 20, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering ...

Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial demonstrating ...

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease (GvHD) is a serious ...

MILAN, March 22, 2022 /PRNewswire/ -- M-Squared Consulting, a consultancy company for life sciences companies in the management of pharmaceutical contracts, has received a first positive signal from EMA's Pandemic Task ...

SANTA BARBARA, Calif.--(BUSINESS WIRE)--#KOLs--Key Opinion Leaders, a company that provides the largest global healthcare platform for benchmarking levels of perceived trustworthiness of healthcare professionals for specific health-related concepts, announced today ...

NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, ...

Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus (CKD-aP) in hemodialysis patientsEuropean ...

CHMP opinion recommending approval based on data from the global Phase 3 HERO study If approved, ORGOVYX® would be the first and only oral androgen deprivation therapy for advanced hormone-sensitive ...